Trial Profile
A Multi-Country and Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in co-Administration With Specific Childhood Vaccines.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Feb 2020 Results of pooled analysis from nine studies including this study published in the Journal of Infectious Diseases.
- 10 Nov 2005 New trial record.